172 related articles for article (PubMed ID: 37060657)
1. Potential of natural products in combination with arsenic trioxide: Investigating cardioprotective effects and mechanisms.
Wang J; Liu YM; Hu J; Chen C
Biomed Pharmacother; 2023 Jun; 162():114464. PubMed ID: 37060657
[TBL] [Abstract][Full Text] [Related]
2. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
4. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Liu P; Han ZC
Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
[TBL] [Abstract][Full Text] [Related]
6. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
Raghu KG; Yadav GK; Singh R; Prathapan A; Sharma S; Bhadauria S
J Environ Pathol Toxicol Oncol; 2009; 28(3):241-52. PubMed ID: 19888912
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
10. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
[TBL] [Abstract][Full Text] [Related]
11. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
Lv J; Wu M; Pang C; Duan R; Zhang H; Tian S; Yang H; Hai X
Biomed Pharmacother; 2023 Jul; 163():114858. PubMed ID: 37172335
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide - An old drug rediscovered.
Emadi A; Gore SD
Blood Rev; 2010; 24(4-5):191-9. PubMed ID: 20471733
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide.
Litzow MR
Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
[TBL] [Abstract][Full Text] [Related]
14. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
16. Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.
Zhang Z; Zhang S; Zhang F; Zhang Q; Wei H; Xiu R; Zhao Y; Sui M
Biol Trace Elem Res; 2024 Jan; 202(1):122-132. PubMed ID: 37097388
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
18. Expanding the use of arsenic trioxide: leukemias and beyond.
Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
[TBL] [Abstract][Full Text] [Related]
19. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
Chen Y; Gu L; Zhou C; Wu X; Gao J; Li Q; Zhu Y; Jia C; Ma Z
Int J Hematol; 2010 May; 91(4):708-10. PubMed ID: 20405253
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
